ALNY
Alnylam
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its “100 Most Innovative Growth Companies” list.
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 16.81B; Volume: 108.19K; AvgVol 3m: 522.89K; Beta: 1.49;
Cost estimate:
P/E: –; EPS: -7.57; EPS growth quarter/prev quarter: 22.80%;
EPS growth this year: -7.00%; EPS growth past 5 years: -10.80%;
EPS ttm: -7.57;
P/S: 50.99; P/B: 11.76; P/Cashflow: 9.14; P/FCF: ;
Sales: 345.18M; Sales growth quarter/prev quarter: 132.70%; Sales growth past 5 years: 34.20%;
Profitability:
Gross Margin: 85.30%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -32.00%; ROE – return on equity: -58.40%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.30%; Insider Transactions:-49.09%;
Institutional Ownership: 97.50%; Institutional Transactions: 2.44%;
Data update: 07.10.2020.